AXGN
Axogen, Inc.
$41.46
-3.13%
$2.2B
No data for this timeframe.
Vol
Market Cap$2.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders7 funds
Inst. Value$229.0M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 7S
Insider Net $-$1.8M
SEC Reports1
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. MN·CIK 0000805928·Prev Close $42.80
Recent Activity
May 8, 2026
SEC
Insider cluster at Axogen shows $1.56M in open-market sales by 5 insiders, including directors and officers, following s
CLUSTER — Impact 3/10
May 8, 2026
Insider
Wendell Amy McBride sold 1,647 shares
Director @ $14.85 ($24.5K)
May 8, 2026
Insider
Wendell Amy McBride sold 1,647 shares
Director @ $0.00 ($0.00)
May 8, 2026
Insider
Wendell Amy McBride sold 1,647 shares
Director @ $42.60 ($70.2K)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
433,473 shares ($14.2M)
Inst.
FMR LLC — ADD
174,000 shares ($5.7M)
Apr 30, 2026
other
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
<p align="justify">ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc.
Price Targets
$50.78
+18.4% upside
Buy
Current $42.87
Low $48.00
Median $50.00
High $55.00
9 analysts
$48.00
$55.00
Analyst Ratings
4Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 29, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Apr 29, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 23, 2026 | Lake Street | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.12 ▼ -16.2% | $0.08 — $0.15 | -1% YoY | 7 |
| Next Q | $0.14 ▼ -5.6% | $0.07 — $0.19 | 20% YoY | 7 |
| Current FY | $0.49 ▼ -8.6% | $0.30 — $0.60 | 68% YoY | 7 |
| Next FY | $0.73 ▼ -4.0% | $0.40 — $1.00 | 49% YoY | 6 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $93.9M | — |
| MORGAN STANLEY | $84.7M | — |
| BANK OF AMERICA CORP | $15.4M | — |
| TWO SIGMA INVESTMENTS, LP | $14.2M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $13.2M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 8, 2026 | Wendell Amy | M | $24.5K |
| May 8, 2026 | Wendell Amy | M | $0.00 |
| May 8, 2026 | Wendell Amy | SELL | $70.2K |
| May 7, 2026 | Hartley Lindsey | M | $20.5K |
| May 7, 2026 | Hartley Lindsey | SELL | $20.9K |
7 institutional holders with $229.0M total value (6,996,969 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,869,955 | $93.9M | 41.0% | — |
| 2 | MORGAN STANLEY | 2,586,870 | $84.7M | 37.0% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 469,097 | $15.4M | 6.7% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 433,473 | $14.2M | 6.2% | DOUBLED +177.3% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 403,987 | $13.2M | 5.8% | NEW |
| 6 | FMR LLC | 174,000 | $5.7M | 2.5% | ADD +29.0% |
| 7 | WELLS FARGO & COMPANY/MN | 59,587 | $2.0M | 0.9% | ADD +47.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 156,331 | 433,473 | +177.3% | $14.2M | 2025-Q4 |
| FMR LLC | ADD | 134,886 | 174,000 | +29.0% | $5.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 40,505 | 59,587 | +47.1% | $2.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 10,960 | 156,331 | +1326.4% | $2.8M | 2025-Q3 |
| FMR LLC | TRIM | 268,873 | 134,886 | -49.8% | $2.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 142,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | EXIT | 61,100 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 62,000 | 142,000 | +129.0% | $1.5M | 2025-Q2 |
| UBS Group AG | ADD | 88,906 | 119,932 | +34.9% | $1.3M | 2025-Q2 |
| NORGES BANK | NEW | — | 61,100 | — | $662.9K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 163,848 | 10,960 | -93.3% | $118.9K | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 40,037 | 261,705 | +553.7% | $4.8M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 163,848 | — | $3.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 22,000 | 62,000 | +181.8% | $1.1M | 2025-Q1 |
| NORGES BANK | EXIT | 77,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 19,108 | 84,752 | +343.5% | $1.4M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 26,007 | 32,760 | +26.0% | $539.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 22,000 | — | $362.6K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 363,764 | — | $5.1M | 2024-Q3 |
9 unique insiders with 7 transactions. Net insider value: -$1.8M ($0.00 bought, $1.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 8, 2026 | Wendell Amy McBride | Director | M | 1,647 | $14.85 | $24.5K |
| May 8, 2026 | Wendell Amy McBride | Director | M | 1,647 | $0.00 | $0.00 |
| May 8, 2026 | Wendell Amy McBride | Director | SELL | 1,647 | $42.60 | $70.2K |
| May 7, 2026 | Hartley Lindsey Marie | CFO | M | 2,500 | $8.20 | $20.5K |
| May 7, 2026 | Hartley Lindsey Marie | CFO | SELL | 478 | $43.67 | $20.9K |
| May 7, 2026 | Quackenbush Doris | Sales VP | SELL | 3,878 | $43.51 | $168.7K |
| May 7, 2026 | Hartley Lindsey Marie | CFO | M | 2,500 | $0.00 | $0.00 |
| May 7, 2026 | Kemp Jens | Chief Marketing Officer | SELL | 4,000 | $43.44 | $173.8K |
| May 7, 2026 | Weiler Kathy Johnson | Director | M | 16,344 | $6.95 | $113.6K |
| May 7, 2026 | Weiler Kathy Johnson | Director | SELL | 16,344 | $44.09 | $720.6K |
| May 7, 2026 | Weiler Kathy Johnson | Director | M | 16,344 | $0.00 | $0.00 |
| May 7, 2026 | JOHNSON JOHN | Director | M | 11,050 | $7.04 | $77.8K |
| May 7, 2026 | JOHNSON JOHN | Director | SELL | 11,050 | $43.26 | $478.0K |
| May 7, 2026 | JOHNSON JOHN | Director | M | 11,050 | $0.00 | $0.00 |
| Mar 16, 2026 | DeVinney Erick Wayne | Chief Innovation Officer | SELL | 5,221 | $32.84 | $171.5K |
| Mar 16, 2026 | DeVinney Erick Wayne | Chief Innovation Officer | F | 2,870 | $32.84 | $94.3K |
| Mar 16, 2026 | DeVinney Erick Wayne | Chief Innovation Officer | M | 6,363 | $0.00 | $0.00 |
| Mar 16, 2026 | Hartley Lindsey Marie | CFO | M | 4,000 | $0.00 | $0.00 |
| Mar 16, 2026 | Hartley Lindsey Marie | CFO | M | 4,000 | $0.00 | $0.00 |
| Mar 16, 2026 | Hartley Lindsey Marie | CFO | F | 1,574 | $32.84 | $51.7K |
| Mar 16, 2026 | DeVinney Erick Wayne | Chief Innovation Officer | M | 6,363 | $0.00 | $0.00 |
| Mar 1, 2026 | Kemp Jens | Chief Marketing Officer | F | 2,952 | $30.65 | $90.5K |
| Mar 1, 2026 | Began Marc A | EVP & General Counsel | M | 11,250 | $0.00 | $0.00 |
| Mar 1, 2026 | DeVinney Erick Wayne | Chief Innovation Officer | F | 11,276 | $30.65 | $345.6K |
| Mar 1, 2026 | Began Marc A | EVP & General Counsel | M | 11,250 | $0.00 | $0.00 |
| Feb 26, 2026 | Kemp Jens | Chief Marketing Officer | A | 50,670 | $0.00 | $0.00 |
| Feb 26, 2026 | Kemp Jens | Chief Marketing Officer | A | 23,000 | $0.00 | $0.00 |
| Feb 26, 2026 | DeVinney Erick Wayne | Chief Innovation Officer | A | 33,780 | $0.00 | $0.00 |
| Feb 26, 2026 | DeVinney Erick Wayne | Chief Innovation Officer | A | 23,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Began Marc A | EVP & General Counsel | A | 23,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Hartley Lindsey Marie | CFO | A | 23,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Began Marc A | EVP & General Counsel | A | 33,780 | $0.00 | $0.00 |
| Feb 26, 2026 | Hartley Lindsey Marie | CFO | A | 17,453 | $0.00 | $0.00 |
| Feb 26, 2026 | DALE MICHAEL D | Chief Executive Officer | A | 98,000 | $0.00 | $0.00 |
| Feb 22, 2026 | Hartley Lindsey Marie | CFO | A | 17,500 | $0.00 | $0.00 |
| Feb 22, 2026 | Hartley Lindsey Marie | CFO | A | 17,500 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 4 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$50.78 mean target
+18.4% upside
Buy (1.22)
$48.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $42.87 |
| Target Low | $48.00 |
| Target Mean | $50.78 |
| Target Median | $50.00 |
| Target High | $55.00 |
| # Analysts | 9 |
| Recommendation | Buy (1.22) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.12 | $0.08 | $0.15 | -1.2% | -16.2% | 0↑ 7↓ | $0.1B | 18.4% | 7 |
| Next Q 2026-09-30 |
$0.14 | $0.07 | $0.19 | 20.2% | -5.6% | 1↑ 5↓ | $0.1B | 17.6% | 7 |
| Current FY 2026-12-31 |
$0.49 | $0.30 | $0.60 | 68.5% | -8.6% | 1↑ 4↓ | $0.3B | 20.3% | 7 |
| Next FY 2027-12-31 |
$0.73 | $0.40 | $1.00 | 49.1% | -4.0% | 2↑ 4↓ | $0.3B | 17.5% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.119 | |
| 7d ago | $0.119 | |
| 30d ago | $0.141 | -0.023 |
| 60d ago | $0.146 | -0.027 |
| 90d ago | $0.139 | -0.020 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 29, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 29, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 23, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 19, 2026 | Wells Fargo | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 4 | 12 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 30, 2026
other
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
<p align="justify">ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
Apr 29, 2026
short_volume
Short Volume: AXGN — 69.7% short (0.4M / 0.5M)
Short: 371,673 | Exempt: 0 | TRF Vol: 533,351 | Short Ratio: 69.7% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
earnings
Axogen, Inc. Reports First Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 20% Growth or $270 million <pre>Raises Full Year Revenue Guidance to at Least 20% Growth or $270 million
Apr 28, 2026
earnings_calendar
AXGN Q1 2026 Earnings Scheduled — 2026-04-28
Apr 6, 2026
short_volume
Short Volume: AXGN — 57.8% short (0.3M / 0.5M)
Short: 296,618 | Exempt: 0 | TRF Vol: 513,171 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
Feb 24, 2026
earnings_calendar
AXGN Q4 2025 Earnings Before Market Open — 2026-02-24
Dec 5, 2025
fda_pdufa
PDUFA: AXGN — Avance Nerve Graft in peripheral nerve defects — 2025-12-05
FDA target action date 2025-12-05 for AXGN (Axogen, Inc.). Drug: Avance Nerve Graft. Indication: peripheral nerve defects. FDA extended PDUFA goal dat